Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:New Microbes New Infect
Autori principali: Cadegiani, F.A., Goren, A., Wambier, C.G., McCoy, J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8262389/
https://ncbi.nlm.nih.gov/pubmed/34249367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nmni.2021.100915
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi